COVID-19 疫苗：了解未知。
COVID-19 vaccines: Knowing the unknown.
机构信息
HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
出版信息
Eur J Immunol. 2020 Jul;50(7):939-943. doi: 10.1002/eji.202048663. Epub 2020 Jun 24.
Abstract
Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain - some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be addressed for COVID-19 vaccine development, and what can be learned from examples of vaccine development in the past. Since the beginning of the outbreak, the research progress on COVID-19 has been remarkable. We are therefore optimistic about the rapid development of COVID-19 vaccine.
摘要
由于 COVID-19 疫情的爆发，针对 SARS-CoV-2 的疫苗开发引起了全球关注。虽然 COVID-19 是由一种新型冠状病毒 SARS-CoV-2 引起的，但之前针对其他冠状病毒疫苗的研究，如 FIPV、SARS 和 MERS，为 COVID-19 疫苗的快速开发提供了有价值的信息。然而，仍存在重要的知识空白，有些是 SARS-CoV-2 特有的，有些则是免疫学和疫苗学的基础。在这里，我们讨论了 COVID-19 疫苗开发需要解决的领域，以及可以从过去的疫苗开发示例中学到什么。自疫情爆发以来，COVID-19 的研究进展显著。因此，我们对 COVID-19 疫苗的快速开发持乐观态度。
相似文献
1
COVID-19 vaccines: Knowing the unknown.COVID-19 疫苗：了解未知。
Eur J Immunol. 2020 Jul;50(7):939-943. doi: 10.1002/eji.202048663. Epub 2020 Jun 24.
2
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?针对冠状病毒感染的疫苗候选者。COVID-19 处于什么位置？
Viruses. 2020 Aug 7;12(8):861. doi: 10.3390/v12080861.
3
Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.COVID-19 疫苗研发的进展与挑战及对 SARS-CoV-2 特异性免疫应答的现有认识。
J Microbiol Biotechnol. 2020 Aug 28;30(8):1109-1115. doi: 10.4014/jmb.2006.06006.
4
SARS-CoV-2: A New Song Recalls an Old Melody.SARS-CoV-2：一首新歌唤起旧旋律。
Cell Host Microbe. 2020 May 13;27(5):692-694. doi: 10.1016/j.chom.2020.04.019.
5
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
6
Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial.正在试验的新型冠状病毒（SARS-CoV-2）疫苗面临的潜在挑战。
Front Immunol. 2020 Sep 29;11:561851. doi: 10.3389/fimmu.2020.561851. eCollection 2020.
7
Progress and Concept for COVID-19 Vaccine Development.新型冠状病毒肺炎疫苗研发进展与理念
Biotechnol J. 2020 Jun;15(6):e2000147. doi: 10.1002/biot.202000147. Epub 2020 May 7.
8
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.基于类似冠状病毒的实验结果开发 SARS-CoV-2 疫苗的潜在佐剂。
Int Immunopharmacol. 2020 Sep;86:106717. doi: 10.1016/j.intimp.2020.106717. Epub 2020 Jun 18.
9
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
10
Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.当前有希望开发有效严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的方法概述。
Int Immunopharmacol. 2020 Nov;88:106928. doi: 10.1016/j.intimp.2020.106928. Epub 2020 Aug 24.
引用本文的文献
1
Predicting death risk analysis in fully vaccinated people using novel extreme regression-voting classifier.使用新型极端回归投票分类器预测完全接种疫苗人群的死亡风险分析
Digit Health. 2022 Jul 21;8:20552076221109530. doi: 10.1177/20552076221109530. eCollection 2022 Jan-Dec.
2
Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects.分析新冠mRNA疫苗的系统生物学效应以评估其安全性和潜在副作用。
Pathogens. 2022 Jun 29;11(7):743. doi: 10.3390/pathogens11070743.
3
Novel extreme regression-voting classifier to predict death risk in vaccinated people using VAERS data.利用 VAERS 数据，通过新型极端回归投票分类器预测接种人群的死亡风险。
PLoS One. 2022 Jun 29;17(6):e0270327. doi: 10.1371/journal.pone.0270327. eCollection 2022.
4
Vaccination Schedule under Conditions of Limited Vaccine Production Rate.疫苗生产速率有限情况下的疫苗接种计划
Vaccines (Basel). 2022 Jan 13;10(1):116. doi: 10.3390/vaccines10010116.
5
Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA.心肌炎与新冠病毒mRNA疫苗：一种涉及双链RNA的机制假说
Future Virol. 2021 Nov. doi: 10.2217/fvl-2021-0280. Epub 2021 Dec 6.
6
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19.关于新型冠状病毒肺炎潜在治疗药物候选物、疫苗的最新综述以及对已提交专利的见解。
Curr Res Pharmacol Drug Discov. 2021;2:100063. doi: 10.1016/j.crphar.2021.100063. Epub 2021 Oct 8.
7
Health and Protective Measures for Seniors during the COVID-19 Pandemic in the Opinion of Polish Society.波兰社会关于 COVID-19 大流行期间老年人的健康和保护措施的意见
Int J Environ Res Public Health. 2021 Sep 1;18(17):9230. doi: 10.3390/ijerph18179230.
8
COVID-19: Myths and Reality.COVID-19：谣言与真相。
Biochemistry (Mosc). 2021 Jul;86(7):800-817. doi: 10.1134/S0006297921070026.
9
COVID-19 vaccines and nanomedicine.COVID-19 疫苗与纳米医学。
Int J Dermatol. 2021 Sep;60(9):1047-1052. doi: 10.1111/ijd.15673. Epub 2021 Jun 5.
10
A systematic review and meta-analysis on correlation of weather with COVID-19.系统评价和荟萃分析天气与 COVID-19 的相关性。
Sci Rep. 2021 May 24;11(1):10746. doi: 10.1038/s41598-021-90300-9.
本文引用的文献
1
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.一种中和性人源抗体结合到了 SARS-CoV-2 的刺突蛋白的 N 端结构域。
Science. 2020 Aug 7;369(6504):650-655. doi: 10.1126/science.abc6952. Epub 2020 Jun 22.
2
Human neutralizing antibodies elicited by SARS-CoV-2 infection.SARS-CoV-2 感染诱导的人体中和抗体。
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
3
Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.通过对固有免疫的控制调节来预防和治疗 COVID-19 疾病。
Eur J Immunol. 2020 Jul;50(7):932-938. doi: 10.1002/eji.202048693. Epub 2020 Jun 15.
4
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
5
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在人血管紧张素转换酶2（hACE2）转基因小鼠中的致病性。
Nature. 2020 Jul;583(7818):830-833. doi: 10.1038/s41586-020-2312-y. Epub 2020 May 7.
6
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.人源单克隆抗体可阻断严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与血管紧张素转换酶2受体的结合。
Cell Mol Immunol. 2020 Jun;17(6):647-649. doi: 10.1038/s41423-020-0426-7. Epub 2020 Apr 20.
7
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.新冠病毒、中东呼吸综合征病毒和严重急性呼吸综合征病毒在非人灵长类动物模型中的比较发病机制。
Science. 2020 May 29;368(6494):1012-1015. doi: 10.1126/science.abb7314. Epub 2020 Apr 17.
8
Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.雪貂中 SARS-CoV-2 的感染和快速传播。
Cell Host Microbe. 2020 May 13;27(5):704-709.e2. doi: 10.1016/j.chom.2020.03.023. Epub 2020 Apr 6.
9
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
10
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.SARS-CoV-2 和 SARS 冠状病毒受体结合域中高度保守的隐蔽表位。
Science. 2020 May 8;368(6491):630-633. doi: 10.1126/science.abb7269. Epub 2020 Apr 3.
Zotero 插件